Is Acetyl-l-carnitine (ALC) clinically effective in treating people with dementia?
Acetyl-L-Carnitine, a randomized controlled trial (Cochrane Database Syst Rev 2003, PMID 12804452) — however, no benefit was found at 52 weeks for Clinical Global Impression, nor for cognition, severity of dementia, or functional ability when measured continuously. All included trials focused only on Alzheimer's disease, not other types of dementia.
Source: Cochrane Database Syst Rev 2003, PMID 12804452 ↗ · Research map · How Magellan grades evidence · evidence confidence: high
Cochrane Database Syst Rev · 2003 · PMID 12804452 · DOI 10.1002/14651858.CD003158
Acetyl-l-carnitine shows limited and potentially chance-driven benefits for global clinical impression in Alzheimer's disease, but no clear objective benefits for cognition or function.
The question
Is Acetyl-l-carnitine (ALC) clinically effective in treating people with dementia?
What they tested
The efficacy of ALC in cognitive decline remains unclear, with early studies suggesting benefit and later, larger studies not supporting these findings.
How they did it
This review identified 11 double-blind, randomized trials comparing ALC with placebo in people with Alzheimer's disease. Data were extracted and analyzed using Revman 4.1 software, primarily focusing on completers. Outcomes assessed included cognitive effects, severity of dementia, functional ability, and clinical global impression.
What they found
Statistically significant treatment effects favoring ALC were observed at 12 and 24 weeks for the number of patients showing improvement as determined by Clinical Global Impression (OR 2.33 at 12 weeks, OR 3.91 at 24 weeks). However, no benefit was found at 52 weeks for Clinical Global Impression, nor for cognition, severity of dementia, or functional ability when measured continuously. There were no statistically significant differences in adverse events between ALC and placebo groups.
| 12 Weeks | 2.33 | |
|---|---|---|
| 24 Weeks | 3.91 |
Odds ratios for improvement as determined by Clinical Global Impression, favoring Acetyl-l-carnitine over placebo at 12 and 24 weeks.
What it means
There is some evidence for ALC's benefit on clinical global impression, but no evidence from objective assessments in other outcome areas. The statistically significant results might be due to chance given the number of comparisons. Currently, there is no evidence to recommend ALC's routine use in clinical practice for dementia.
Limitations
All included trials focused only on Alzheimer's disease, not other types of dementia. Methodological differences and assessment tools varied widely across early and later studies, making comparisons difficult. The statistically significant findings for clinical global impression might be due to chance given the multiple comparisons. The review primarily used completers' data rather than intention-to-treat.
The paper at a glance
| Magellan’s evidence label | mitochondrial fatty-acid transport (our label for this citation — see PubMed for the paper’s own title and authors) |
|---|---|
| Journal | Cochrane Database Syst Rev |
| Year | 2003 |
| PMID | 12804452 ↗ |
| DOI | 10.1002/14651858.CD003158 ↗ |
| Topic | Brain, cognition & mood |
Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗
Where Magellan uses this paper
This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.
Acetyl-L-Carnitine (ALCAR)
Randomized trials and meta-analyses report modest benefits on cognition in mild cognitive impairment and mild Alzheimer's disease, on depressive symptoms — two meta-analyses (2018 and 2026) find efficacy comparable to antidepressants with fewer side effects, strongest in older adults — and on physical and mental…
L-Carnitine
Older and mostly small randomized trials, pooled in meta-analyses, suggest that L-carnitine given around the time of an acute myocardial infarction is associated with reduced all-cause mortality, ventricular arrhythmias and angina, and with attenuated left-ventricular dilation and smaller infarct size, effects…
Acetyl-L-carnitine (ALCAR) is the acetylated ester of the amino-acid derivative L-carnitine, a compound…
L-carnitine is a naturally occurring, vitamin-like compound synthesized from the amino acids lysine and…
Research describes the compound or intervention studied. It is not a claim about any specific product.
Molecules & mechanisms in this paper
Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.
Cite this page
These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.
Magellan Longevity. (2026). Is Acetyl-l-carnitine (ALC) clinically effective in treating people with dementia? [Plain-English summary of Cochrane Database Syst Rev 2003, PMID 12804452, DOI 10.1002/14651858.CD003158]. Magellan Longevity. https://magellanlongevity.com/study/s126.html@misc{magellan_s126,
title = {Is Acetyl-l-carnitine (ALC) clinically effective in treating people with dementia?},
author = {{Magellan Longevity}},
year = {2026},
howpublished = {\url{https://magellanlongevity.com/study/s126.html}},
note = {Plain-English summary of PubMed PMID 12804452; DOI 10.1002/14651858.CD003158; Cochrane Database Syst Rev 2003. Reviewed by Gabriel Radu, DO},
urldate = {2026-08-11}
}https://magellanlongevity.com/study/s126.htmlRelated studies in the Magellan library
- What are the effects of various oral maintenance dosages of L-carnitine on all-cause mortality…BMC Cardiovasc Disord · 2014 · PMID 25044037
- Acetyl-L-carnitine Slows the Progression from Prefrailty to Frailty in Older SubjectsCurr Pharm Des · 2022 · PMID 36043711
- L-carnitine in the secondary prevention of cardiovascular diseaseMayo Clin Proc · 2013 · PMID 23597877
- Regulation of structural and functional synapse density by L-threonate through intraneuronal…Neuropharmacology · 2016 · PMID 27178134
- Insights into the therapeutic strategies for aging and aging-associated diseasesSignal Transduction and Targeted Therapy · 2026 · PMID 42225652
- Dietary supplements for treating osteoarthritisBr J Sports Med · 2018 · PMID 29018060
Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →